MX393606B - Inhibidores de poli-adp ribosa polimerasa (parp) - Google Patents

Inhibidores de poli-adp ribosa polimerasa (parp)

Info

Publication number
MX393606B
MX393606B MX2019007870A MX2019007870A MX393606B MX 393606 B MX393606 B MX 393606B MX 2019007870 A MX2019007870 A MX 2019007870A MX 2019007870 A MX2019007870 A MX 2019007870A MX 393606 B MX393606 B MX 393606B
Authority
MX
Mexico
Prior art keywords
parp
poly
inhibitors
ribose polymerase
adp ribose
Prior art date
Application number
MX2019007870A
Other languages
English (en)
Other versions
MX2019007870A (es
Inventor
Arthur Kluge
Bharat Lagu
Nan Ji
Taisuke Takahashi
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of MX2019007870A publication Critical patent/MX2019007870A/es
Publication of MX393606B publication Critical patent/MX393606B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con una composicion farmaceutica que comprende un vehiculo aceptable farmaceuticamente o un diluyente y un compuesto representado por la siguiente formula estructural : (ver formula) la presente invencion tambien se relaciona con un metodo para tratar un sujeto con una enfermedad que puede mejorarse mediante la inhibicion de la poli(ADP-ribosa)polimerasa (PARP); en la memoria descriptiva se proveen las definiciones de las variables.
MX2019007870A 2016-12-30 2017-12-28 Inhibidores de poli-adp ribosa polimerasa (parp) MX393606B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440581P 2016-12-30 2016-12-30
PCT/US2017/068636 WO2018125961A1 (en) 2016-12-30 2017-12-28 Poly-adp ribose polymerase (parp) inhibitors

Publications (2)

Publication Number Publication Date
MX2019007870A MX2019007870A (es) 2019-08-16
MX393606B true MX393606B (es) 2025-03-19

Family

ID=61007849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007870A MX393606B (es) 2016-12-30 2017-12-28 Inhibidores de poli-adp ribosa polimerasa (parp)

Country Status (33)

Country Link
US (2) US11034670B2 (es)
EP (1) EP3562822B1 (es)
JP (1) JP7141399B2 (es)
KR (1) KR102606799B1 (es)
CN (1) CN110167926B (es)
AR (1) AR110706A1 (es)
AU (1) AU2017388376B2 (es)
CA (1) CA3047137A1 (es)
CO (1) CO2019007906A2 (es)
CY (1) CY1124565T1 (es)
DK (1) DK3562822T3 (es)
EA (1) EA201991412A1 (es)
ES (1) ES2875841T3 (es)
HR (1) HRP20210887T1 (es)
HU (1) HUE054382T2 (es)
IL (1) IL267676B (es)
JO (1) JOP20190115B1 (es)
LT (1) LT3562822T (es)
MA (1) MA47165B1 (es)
MD (1) MD3562822T2 (es)
MX (1) MX393606B (es)
MY (1) MY199045A (es)
PH (1) PH12019501529A1 (es)
PL (1) PL3562822T3 (es)
PT (1) PT3562822T (es)
RS (1) RS61895B1 (es)
SA (1) SA519401894B1 (es)
SI (1) SI3562822T1 (es)
SM (1) SMT202100321T1 (es)
TW (1) TWI773718B (es)
UA (1) UA124777C2 (es)
WO (1) WO2018125961A1 (es)
ZA (2) ZA201904004B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52648A (fr) * 2015-10-07 2021-10-13 Mitobridge Inc Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
PL3562822T3 (pl) * 2016-12-30 2021-09-13 Mitobridge, Inc. Inhibitory polimerazy poli(adp-rybozy) (parp)
MX2022005234A (es) * 2019-10-30 2022-09-07 Digmbio Inc Derivados de isoquinolinona, procedimiento para su preparacion y composicion farmaceutica para la prevencion o el tratamiento de enfermedades relacionadas con la poli(adp-ribosa) polimerasa-1, que constituye los mismos como principio activo.
MX2023012361A (es) * 2021-04-22 2023-10-31 Wigen Biomedicine Tech Shanghai Co Ltd Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
KR20240057402A (ko) * 2021-07-23 2024-05-02 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 그람 음성 박테리아 유출 펌프 억제제
CN113603630B (zh) * 2021-08-10 2023-06-27 苏州小栗医药科技有限公司 一种4-苯基哌啶盐酸盐的合成方法
WO2024061768A1 (en) 2022-09-19 2024-03-28 Basf Se Azole pesticidal compounds
EP4617262A1 (en) 2022-11-07 2025-09-17 Kyoto University Nitrogen-containing heterocyclic compound
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN120917007A (zh) * 2023-05-19 2025-11-07 上海海和药物研究开发股份有限公司 一种芳基脲类parp1抑制剂、其制备方法及用途
CN117024357A (zh) * 2023-07-03 2023-11-10 潍坊医学院 一种针对brca突变的选择性抑制剂及其用途
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
CN117510404A (zh) * 2023-11-29 2024-02-06 山西永津集团有限公司 一种4-氨基烟酸的制备方法
WO2025111705A1 (en) * 2023-11-30 2025-06-05 Waverley Pharma Inc. Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
CN118084678B (zh) * 2024-03-01 2024-09-06 长沙唯楚医药科技有限公司 一种2-溴-6-氟苯胺的制备方法
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082268A1 (en) 2000-03-20 2002-06-27 Yun Gao Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
US20030087917A1 (en) 2000-03-27 2003-05-08 Dorothea Strack Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2005217320B2 (en) 2004-02-26 2011-07-21 Aska Pharmaceuticals Co., Ltd. Pyrimidine derivative
US8039674B2 (en) 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
ATE540936T1 (de) * 2004-06-30 2012-01-15 Janssen Pharmaceutica Nv Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
JP2009501235A (ja) 2005-07-15 2009-01-15 シェーリング コーポレイション 癌処置において有用なキナゾリン誘導体
JPWO2007099828A1 (ja) 2006-02-23 2009-07-16 塩野義製薬株式会社 環式基で置換された含窒素複素環誘導体
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
JP6423875B2 (ja) 2013-07-31 2018-11-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ オキソキナゾリニル−ブタンアミド誘導体
EP3140295B1 (en) 2014-05-07 2018-09-12 Merck Patent GmbH Heterocyclyl-butanamide derivatives
CN105924434A (zh) * 2015-02-28 2016-09-07 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
WO2018026371A1 (en) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Dual nav1.2/5ht2a inhibitors for treating cns disorders
PL3562822T3 (pl) * 2016-12-30 2021-09-13 Mitobridge, Inc. Inhibitory polimerazy poli(adp-rybozy) (parp)

Also Published As

Publication number Publication date
JP2020512298A (ja) 2020-04-23
BR112019011676A2 (pt) 2019-10-15
TW201834657A (zh) 2018-10-01
EP3562822A1 (en) 2019-11-06
PL3562822T3 (pl) 2021-09-13
MY199045A (en) 2023-10-11
IL267676B (en) 2021-09-30
CN110167926B (zh) 2022-09-13
PH12019501529A1 (en) 2020-09-14
KR20190098760A (ko) 2019-08-22
ZA202003310B (en) 2021-08-25
CN110167926A (zh) 2019-08-23
US11993585B2 (en) 2024-05-28
EP3562822B1 (en) 2021-03-10
AU2017388376A1 (en) 2019-07-04
HUE054382T2 (hu) 2021-09-28
PT3562822T (pt) 2021-06-02
AU2017388376B2 (en) 2022-01-06
TWI773718B (zh) 2022-08-11
EA201991412A1 (ru) 2019-11-29
SI3562822T1 (sl) 2021-08-31
MD3562822T2 (ro) 2021-07-31
NZ754385A (en) 2024-07-05
US20220033380A1 (en) 2022-02-03
SMT202100321T1 (it) 2021-07-12
RS61895B1 (sr) 2021-06-30
KR102606799B1 (ko) 2023-11-28
MA47165B1 (fr) 2021-06-30
ES2875841T3 (es) 2021-11-11
IL267676A (en) 2019-08-29
ZA201904004B (en) 2022-12-21
CO2019007906A2 (es) 2019-10-21
WO2018125961A1 (en) 2018-07-05
DK3562822T3 (en) 2021-05-03
HRP20210887T1 (hr) 2021-07-23
CA3047137A1 (en) 2018-07-05
LT3562822T (lt) 2021-06-10
JOP20190115A1 (ar) 2019-05-20
US11034670B2 (en) 2021-06-15
JP7141399B2 (ja) 2022-09-22
UA124777C2 (uk) 2021-11-17
JOP20190115B1 (ar) 2023-09-17
SA519401894B1 (ar) 2023-02-19
AR110706A1 (es) 2019-04-24
WO2018125961A8 (en) 2019-05-23
MX2019007870A (es) 2019-08-16
US20200071299A1 (en) 2020-03-05
CY1124565T1 (el) 2022-07-22
MA47165A (fr) 2019-11-06

Similar Documents

Publication Publication Date Title
MX393606B (es) Inhibidores de poli-adp ribosa polimerasa (parp)
NI201800093A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
EA201690094A1 (ru) Ингибиторы syk
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MX388591B (es) Derivados de pirazolopirimidina como inhibidor de cinasa.
MA38922A2 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
CO2017012067A2 (es) Derivado de pirido[3,4–d]pirimidina y sal farmacéuticamente aceptable de éste
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
EA201990833A1 (ru) Соединение пиридина
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
MX374439B (es) Compuesto de piridona como inhibidor de c-met
NZ746906A (en) Oxaborole esters and uses thereof
EA201692300A1 (ru) Производные карбоксамида
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
EA202191885A3 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4